newscaster

Envveno Medical Nails It: Final Implants in Pre-Clinical GLP Study are a Resounding Success!

Successful Completion of All Planned Implants in GLP Study Marks Major Milestone for enVVeno Medical Corporation A Game-Changer in Venous Disease Treatment Today, enVVeno Medical Corporation (Nasdaq:NVNO) is celebrating a significant achievement in the field of venous disease treatment. The successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical…

Read More

Important Reminder for Shareholders: Don’t Miss the Deadline to Become a Lead Plaintiff in Kyverna Therapeutics Inc. Lawsuit!

Embracing Change: A Call to Action for Kyverna Therapeutics Shareholders New York, Dec. 16, 2024 /PRNewswire/ — As we navigate through the complexities of the financial world, it is crucial for shareholders to stay informed and empowered. The recent notice issued by The Gross Law Firm to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) serves…

Read More

Why Sea Limited is Still a Worthy Investment: A Reiterated Buy Recommendation

SE’s Successful Turnaround and Growth Prospects Accelerating E-commerce Sales Sea Limited (SE) has seen a remarkable reversal from its previous cash burn, driven by accelerating e-commerce sales. The company’s e-commerce segment, Shopee, has experienced rapid growth in various markets, solidifying its position as a key player in the industry. With the increasing shift towards online…

Read More

Join the Fight Against Fraud: Investors with Losses Welcome to Join The Schall Law Firm in Case Against Customers Bancorp Inc.

The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Customers Bancorp, Inc. Investor Alert: The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Customers Bancorp, Inc. (“Customers Bancorp” or “the Company”) (NYSE:CUBI) for violations of 10(b) and 20(a) of the Securities Exchange Act…

Read More

NewAmsterdam Pharma Celebrates Successful Upsized $479 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, with Underwriters Fully Exercising Option to Purchase

Welcome to the NewAmsterdam Pharma Company Blog! Exciting News from NewAmsterdam Pharma Company NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a leading biopharmaceutical company, recently announced the successful closing of a public offering. This offering marked a significant milestone for the company as they work towards developing…

Read More